A January 13 study published in JAMA Network Open looks at the “Effect of Bimagrumab vs. Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity.” This phase 2 RCT looked and asked, “What are the effects of bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth on total body fat mass and glycemic control in patients with type 2 diabetes and excess adiposity?” The findings were notable: 75 patients with type 2 diabetes and a BMI from 28-40 got bimagrumab or a placebo over 48 weeks with all participants receiving diet and exercise advice, and those who got the drug, “had a significantly larger decrease in total body fat mass and glycated hemoglobin and increase in lean mass, compared with patients who received placebo.” The authors suggest that this result is due to a blockade of the activin receptor, which may provide “a novel pharmacologic approach for managing patients with type 2 diabetes with excess adiposity.” And prior studies have shown improved insulin resistance and adipose tissue loss with bimagrumab.
Novel Help for Excess Adiposity
The study (NCT03005288) sought to “evaluate the efficacy and safety of bima...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).